Treatment options for severe CRSwNP are limited. Dupilumab is a safe, well-tolerated, and effective alternative in patients with poor control of symptoms, corticosteroid-dependent disease, and high rates of recurrence of nasal polyps after surgery.
Keywords: DUPIXENT; anti–IL‐13; anti–IL‐4; biologic agents; chronic rhinosinusitis; dupilumab; monoclonal antibody; nasal polyposis; type 2 inflammation.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.